AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Journal of Geriatric Cardiology Article
PDF (9 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Open Access

Valvular heart disease and cardiomyopathy in China: epidemiology and current treatments

The Writing Committee of the Report on Cardiovascular Health and Diseases in China
Show Author Information

Abstract

The Annual Report on Cardiovascular Health and Diseases in China (2022) intricate landscape of cardiovascular health in China. In connection with the previous section, this ninth section of the report offers a comprehensive analysis of valvular heart disease and cardiomyopathy. Although rheumatic valve disease is still the main cause of valvular heart disease in China, with the aging of the population and the improvement of living standards, the prevalence of degenerative valvular heart disease is on the rise. Because many patients with valvular heart disease have only mild to moderate valve stenosis or insufficiency, and no symptoms, the detection rate in the population is low and late, resulting in many patients been in the severe late stage of disease at visit, increasing the difficulty of treatment and affecting effectiveness and prognosis. Therefore, we should strengthen the examination and screening of valvular heart disease in order to find and prevent it as early as possible. In addition, compared with other diseases, the treatment of valvular heart disease needs more and higher technical support (surgery, intervention, etc). However, not all hospitals can provide relevant technologies. At present, the treatment of valvular heart disease is still mainly concentrated in the provincial hospitals. It is necessary to carry out more professional training so that more doctors and hospitals can participate in the treatment of valvular heart disease. Cardiomyopathy is a group of myocardial diseases with abnormal myocardial structure and/or function, but couldn’t be explained by hypertension, coronary atherosclerosis, valvular heart disease and congenital heart disease. It includes hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), arrhythmogenic cardiomyopathy (also known as arrhythmogenic right ventricular cardiomyopathy), restrictive cardiomyopathy (RCM) and undifferentiated cardiomyopathy.

References

[1]

Yang Y, Wang ZW, Chen Z, et al. Current status and etiology of valvular heart disease in China: a population-based survey. BMC Cardiovasc Disord 2021; 21: 339.
Crossref Google Scholar
[2]

Wang YS, Wu BT, Li J, et al. Distribution patterns of valvular and vascular complications in bicuspid aortic valve. Int Heart J 2020; 61: 273−280.
Crossref Google Scholar
[3]

He SF, Jiang JR, Liu FZ, et al. Prevalence and modifiable risk factors of degenerative valvular heart disease among elderly population in southern China. J Geriatr Cardiol 2021; 18: 523−533.
Crossref Google Scholar
[4]

He SF, Deng H, Jiang JR, et al. The evolving epidemiology of elderly with degenerative valvular heart disease: The Guangzhou (China) Heart Study. Biomed Res Int 2021; 2021: 9982569.
Crossref Google Scholar
[5]

Jin L, Zhang GX, Han L, et al. Baseline and outcome characteristics of multiple valve surgery compared with single valve procedures in mainland China: a multicenter experience. Heart Surg Forum 2019; 22: E486−E493.
Crossref Google Scholar
[6]

Pang YX, Liu SP, Yan LN, et al. Associations of long-term exposure to traffic-related air pollution with risk of valvular heart disease based on a cross-sectional study. Ecotoxicol Environ Saf 2021; 209: 111753. DOI: 10.1016/j.ecoenv. 2020.111753.
Crossref Google Scholar
[7]

Jiang SL, Zhang HJ, Wei SX, et al. Left atrial appendage exclusion is effective in reducing postoperative stroke after mitral valve replacement. J Card Surg 2020; 35: 3395−3402.
Crossref Google Scholar
[8]

Fu JT, Li Y, Zhang HB, et al. Outcomes of mitral valve repair compared with replacement for patients with rheumatic heart disease. J Thorac Cardiovasc Surg 2021; 162: 72−82,e7.
Crossref Google Scholar
[9]

Liu LL, Chen S, Shi J, et al. Transcatheter aortic valve replacement in aortic regurgitation. Ann Thorac Surg 2020; 110: 1959−1966.
Crossref Google Scholar
[10]

Li YM, Xiong TY, Xu K, et al. Characteristics and outcomes following transcatheter aortic valve replacement in China: a report from China aortic valve transcatheter replacement registry (CARRY). Chin Med J (Engl) 2021; 134: 2678−2684.
Crossref Google Scholar
[11]

Lu FL, An Z, Ma Y, et al. Transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Heart 2021; 107: 1664−1670.
Crossref Google Scholar
[12]
Zhang HB, Meng X, Wang SX, et al. [Valve-in-valve technique for transcatheter treatment of bioprosthetic mitral valve failure]. Zhonghua Xiongxin Xueguan Waike Zazhi 2019; 35: 331–333. [Article in Chinese].
[13]

Lu S, Song K, Yao W, et al. Simplified, minimally invasive, beating-heart technique for redo isolated tricuspid valve surgery. J Cardiothorac Surg 2020; 15: 146−151.
Crossref Google Scholar
[14]

Ou-Yang WB, Qureshi S, Ge JB, et al. Multicenter comparison of percutaneous and surgical pulmonary valve replacement in large RVOT. Ann Thorac Surg 2020; 110: 980−987.
Crossref Google Scholar
[15]

Jiao YQ, Luo TG, Meng X, et al. Decade-long mitral valve surgery trends and rheumatic heart disease: a review of mitral valve surgery in a large Chinese cardiovascular center. Ann Palliat Med 2022; 11: 1160−1169.
Crossref Google Scholar
[16]
Sun XL, Wang D, Liu J, et al. [Research on the changing trend of cardiomyopathy disease spectrum - Analysis of outpatient and inpatient data from Fuwai Hospital]. Zhongguo Fenzi Xinzangbingxue Zazhi 2020; 20: 3479–3483. [Article in Chinese].
[17]
Li ZP, Han L, Pediatric Cardiovascular Group of Chinese Medical Association Pediatrics Branch, Children's Cardiomyopathy Precision Diagnosis and Treatment Collaboration Group. [Analysis of 4981 hospitalized children with cardiomyopathy in 33 domestic hospitals from 2006 to 2018]. Zhonghua Shiyong Erke Linchuang Zazhi 2021; 36: 983–989. [Article in Chinese].
[18]

Chan WX, Yang SW, Wang J, et al. Clinical characteristics and survival of children with hypertrophic cardiomyopathy in China: A multicentre retrospective cohort study. EClinicalMedicine 2022; 49: 101466.
Crossref Google Scholar
[19]

Zou YB, Song L, Wang ZM, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med 2004; 116: 14−18.
Crossref Google Scholar
[20]

Wang JZ, Wang YL, Zou YB, et al. Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy. Eur J Heart Fail 2014; 16: 950−957.
Crossref Google Scholar
[21]
Wang ZM, Zou YB, Song L, et al. [Prevalence of hypertrophic cardiomyopathy in 8080 adults by echocardiography]. Zhonghua Xinxueguanbing Zazhi 2004; 32: 1090–1094. [Article in Chinese].
[22]
Li SE, Hou J, Wang T, et al. [Prevalence of dilated cardiomyopathy in non-Keshan disease areas in northern China]. Zhongguo Difangbing Fangzhi Zazhi 2013; 28: 184–187. [Article in Chinese].
[23]
Cardiovascular Disease Branch of Chinese Medical Association. [A retrospective survey of hospitalized cases of chronic heart failure in some areas of China in 1980, 1990, and 2000]. Zhonghua Xinxueguanbing Zazhi 2002; 30: 450–454. [Article in Chinese].
[24]

Wu GX, Liu LW, Zhou ZY, et al. An East Asian-specific common variant in TNNI3 predisposes to hypertrophic cardiomyopathy. Circulation 2020; 142: 2086−2089.
Crossref Google Scholar
[25]

Bao JR, Wang JZ, Yao Y, et al. Correlation of ventricular arrhythmias with genotype in arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013; 6: 552−556.
Crossref Google Scholar
[26]

Chen L, Rao M, Chen X, et al. A founder homozygous DSG2 variant in East Asia results in ARVC with full penetrance and heart failure phenotype. Int J Cardiol 2019; 274: 263−270.
Crossref Google Scholar
[27]
Rao M, Guo GR, Li MM, et al. The homozygous variant c. 245G>A/p. G82D in PNPLA2 is associated with arrhythmogenic cardiomyopathy phenotypic manifestations. Clin Genet 2019; 96: 532–540.
Crossref
[28]
Ma L, Wang YB, Tang X, et al. [Screening for ARVC plakoglobin gene mutations in the population of Yunnan unexplained sudden death area in Xiangyun County, Dali Prefecture, Yunnan Province]. Zhonghua Difangbingxue Zazhi 2021; 40: 605–609. [Article in Chinese].
[29]
Xu J, Ma WZ, Wang JL, et al. [Investigation of familial dilated cardiomyopathy and analysis of its genetic characteristics]. Zhonghua Xinxueguanbing Zazhi 1994; 22(4): 263–264. [Article in Chinese].
[30]

Sun HR, Hao XY, Wang X, et al. Genetics and clinical features of noncompaction cardiomyopathy in the fetal population. Front Cardiovasc Med 2021; 7: 617561.
Crossref Google Scholar
[31]
Precision Cardiovascular Disease Group of Chinese Medical Association Cardiovascular Disease Branch, Precision Cardiovascular Disease Branch of China International Exchange and Promotion Association for Medical and Healthcare, Editorial Board of Chinese Journal of Cardiovascular Diseases. [Guidelines for genetic diagnosis of monogenic hereditary cardiovascular diseases]. Zhonghua Xinxueguanbing Zazhi 2019; 47: 175–196. [Article in Chinese].
[32]
Children's Cardiomyopathy Precision Diagnosis and Treatment Collaboration Group of Pediatric Cardiovascular Group, Chinese Medical Association Pediatrics Branch, Editorial Board of Chinese Journal of Practical Pediatrics. [Expert consensus on the diagnosis of hypertrophic cardiomyopathy in Chinese children]. Zhongguo Shiyong Erke Zazhi 2019; 34: 329–334. [Article in Chinese].
[33]
Writing Group of Chinese Guidelines for Diagnosis and Treatment of Adult Hypertrophic Cardiomyopathy, Chinese Medical Association Cardiovascular Disease Branch, Editorial Board of Chinese Journal of Cardiovascular Diseases. [Guidelines for diagnosis and treatment of adult hypertrophic cardiomyopathy in China]. Zhonghua Xinxueguanbing Zazhi 2017; 45: 1015–1032. [Article in Chinese].
[34]
Sun JH, Han S, Hu JZ, et al. [Clinical practice guidelines for hereditary cardiomyopathy]. Zhonghua Yixue Yichuanxue Zazhi 2020; 37: 300–307. [Article in Chinese].
[35]

Liu J, Wu GX, Zhang C, et al. Improvement in sudden cardiac death risk prediction by the enhanced American College of Cardiology/American Heart Association strategy in Chinese patients with hypertrophic cardiomyopathy. Heart Rhythm 2020; 17: 1658−1663.
Crossref Google Scholar
[36]

Li XF, Fan XH, Li S, et al. A novel risk stratification score for sudden cardiac death prediction in middle-aged, nonischemic dilated cardiomyopathy patients: The ESTIMATED score. Can J Cardiol 2020; 36: 1121−1129.
Crossref Google Scholar
[37]
Zhang M, Sun XL, Wu GX, et al. [Clinical and genetic characteristics of patients with different types of non-obstructive hypertrophic cardiomyopathy]. Zhonghua Xinxueguanbing Zazhi 2021; 49: 593–600. [Article in Chinese].
[38]
Liu J, Wang D, Ruan JY, et al. Identification of heart failure with preserved ejection fraction helps risk stratification for hypertrophic cardiomyopathy. BMC Med 2022; 26; 20: 21. DOI: 10.1186/s12916-021-02219-7.
Crossref
[39]

Zhang HD, Ding L, Weng SX, et al. Characteristics and long-term ablation outcomes of supraventricular arrhythmias in hypertrophic cardiomyopathy: A 10-year, single-center experience. Front Cardiovasc Med 2021; 8: 766571.
Crossref Google Scholar
[40]

Zhang J, Zhu C, Nie C, et al. Impact of body mass index on postoperative atrial fibrillation in patients with hypertrophic cardiomyopathy undergoing septal myectomy. J Am Heart Assoc 2022; 11: e023152.
Crossref Google Scholar
[41]
Deng YQ, Chen ZQ, Hu LL, et al. Decreased eGFR is associated with ischemic stroke in patients with dilated cardiomyopathy. Clin Appl Thromb Hemost 2019; 25. DOI: 10.1177/1076029619866909.
Crossref
[42]
Lai L, Jiang R, Fang W, et al. Prognostic impact of right bundle branch block in hospitalized patients with idiopathic dilated cardiomyopathy: a single-center cohort study. J Int Med Res 2018; 48. DOI: 10.1177/0300060518801478.
Crossref
[43]

Xu YW, Lin JY, Liang YD, et al. Prognostic value of left ventricular remodelling index in idiopathic dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging 2021; 22: 1197−1207.
Crossref Google Scholar
[44]

Wang X, Zhang X, Cao K, et al. Cardiac disruption of SDHAF4-mediated mitochondrial complex II assembly promotes dilated cardiomyopathy. Nat Commun 2022; 13: 3947.
Crossref Google Scholar
[45]

Feng Y, Cai L, Hong W, et al. Rewiring of 3D chromatin topology orchestrates transcriptional reprogramming and the development of human dilated cardiomyopathy. Circulation 2022; 145: 1663−1683.
Crossref Google Scholar
[46]

Chen XY, Li L, Cheng HB, et al. Early left ventricular involvement detected by cardiovascular magnetic resonance feature tracking in arrhythmogenic right ventricular cardiomyopathy: The effects of left ventricular late gadolinium enhancement and right ventricular dysfunction. J Am Heart Assoc 2019; 8: e012989.
Crossref Google Scholar
[47]

Chen K, Rao M, Guo G, et al. Recessive variants in plakophilin-2 contributes to early-onset arrhythmogenic cardiomyopathy with severe heart failure. Europace 2019; 21: 970−977.
Crossref Google Scholar
[48]

Song JP, Chen L, Chen X, et al. Elevated plasma β-hydroxybutyrate predicts adverse outcomes and disease progression in patients with arrhythmogenic cardiomyopathy. Sci Transl Med 2020; 12: eaay8329.
Crossref Google Scholar
[49]

Akdis D, Chen L, Saguner AM, et al. Novel plasma biomarkers predicting biventricular involvement in arrhythmogenic right ventricular cardiomyopathy. Am Heart J 2022; 244: 66−76.
Crossref Google Scholar
[50]

Chen L, Song J, Chen X, et al. A novel genotype-based clinicopathology classification of arrhythmogenic cardiomyopathy provides novel insights into disease progression. Eur Heart J 2019; 40: 1690−1703.
Crossref Google Scholar
[51]

Duru F, Hauer R. Multiple facets of arrhythmogenic cardiomyopathy: the Fuwai classification of a unique disease based on clinical features, histopathology, and genotype. Eur Heart J 2019; 40: 1704−1706.
Crossref Google Scholar
[52]
Ren J, Chen L, Hu SS. [Diagnostic efficacy of the 2010 diagnostic criteria for arrhythmogenic cardiomyopathy in patients with different Fuwai classifications]. Zhongguo Xunhuan Zazhi 2022; 37: 234–238. [Article in Chinese].
[53]

Wang W, Wang J, Yao K, et al. Metabolic characterization of hypertrophic cardiomyopathy in human heart. Nat Cardiovasc Res 2022; 1: 445−461.
Crossref Google Scholar
[54]
Li HJ, Song YH, Zhu XD, et al. [Analysis of mid-term and long-term results of septal myectomy for hypertrophic obstructive cardiomyopathy in a single center]. Zhongguo Xunhuan Zazhi 2016; 31: 573–577. [Article in Chinese].
[55]
Nie CR, Zhu CS, Xiao MH, et al. [Early results of septal myectomy via combined transaortic and transapical approach for complex hypertrophic obstructive cardiomyopathy]. Zhonghua Xiongxin Xueguan Waike Zazhi 2021; 37: 733–736. [Article in Chinese].
[56]
Tang YJ, Liu J, Chen Z, et al. [Early results of thoracoscopic trans-mitral septal myectomy for hypertrophic obstructive cardiomyopathy]. Zhonghua Xiongxin Xueguan Waike Zazhi 2020; 36: 472–477. [Article in Chinese].
[57]
Liu R, Qiao SB, Hu FH, et al. [Long-term prognosis and influencing factors of percutaneous transluminal septal myocardial ablation for hypertrophic cardiomyopathy]. Zhonghua Xinxueguanbing Zazhi 2016; 44: 771–776. [Article in Chinese].
[58]
Zheng SW, Shi HY, Dai JJ, et al. [Long-term survival of patients with obstructive hypertrophic cardiomyopathy after percutaneous transluminal septal myocardial ablation]. Zhonghua Xinxueguanbing Zazhi 2020; 48: 294–301. [Article in Chinese].
[59]

Zhou M, Ta S, Hahn RT, et al. Percutaneous intramyocardial septal radiofrequency ablation in patients with drug-refractory hypertrophic obstructive cardiomyopathy. JAMA Cardiol 2022; 7: 529−538.
Crossref Google Scholar
[60]
Jia YH, Lin Y, Liu J, et al. [Clinical application of percutaneous endocardial septal radiofrequency ablation under intracardiac ultrasound guidance for hypertrophic obstructive cardiomyopathy with syncope]. Zhongguo Xunhuan Zazhi 2020; 35: 638–644. [Article in Chinese].
[61]
Dai Y, Chen KP, Hua W, et al. [Current status of clinical application of implantable cardioverter-defibrillators (A registration study of 20 hospitals)]. Zhonghua Xinlvshichangxue Zazhi 2017; 21: 26–30. [Article in Chinese].
[62]
Hu SS. [Current status of heart transplantation in China]. Zhonghua Qiguan Yizhi Zazhi 2017; 38: 449–454. [Article in Chinese].
[63]
Chinese Expert Consensus Group on Septal Myocardial Ablation for Hypertrophic Obstructive Cardiomyopathy. [Chinese expert consensus on septal myocardial ablation for hypertrophic obstructive cardiomyopathy]. Zhongguo Xinxueguanbing Yanjiu 2012; 10: 1–7. [Article in Chinese].
[64]
Pediatric Cardiovascular Group of Chinese Medical Association Pediatrics Branch, Editorial Board of Chinese Journal of Pediatrics. [Recommendations for genetic testing of cardiomyopathy in children]. Zhonghua Erke Zazhi 2013; 51: 595–597. [Article in Chinese].
[65]
Cardiovascular Disease Branch of Chinese Medical Association, Cardiovascular Physician Branch of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Cardiovascular Diseases. [Chinese expert consensus on clinical application of cardiac magnetic resonance imaging in cardiomyopathy]. Zhonghua Xinxueguanbing Zazhi 2015; 43: 673–681. [Article in Chinese].
[66]
Heart Failure Professional Committee of Chinese Medical Doctor Association, Editorial Board of Chinese Journal of Heart Failure and Cardiomyopathy. [Chinese guidelines for management of hypertrophic cardiomyopathy 2017]. Zhonghua Xinli Shuairuo He Xinjibing Zazhi (Chinese and English) 2017; 1: 65–86. [Article in Chinese].
[67]
Cardiovascular Disease Branch of Chinese Medical Association, Chinese Myocarditis and Cardiomyopathy Collaborative Group. [Chinese guidelines for diagnosis and treatment of dilated cardiomyopathy]. Linchuang Xinxueguanbing Zazhi 2018; 34: 421–434. [Article in Chinese].
[68]
Ultrasound Medical Branch of Chinese Medical Association Echocardiography Group, Echocardiography Professional Committee of Chinese Society of Ultrasound Medicine Engineering. [Expert consensus on echocardiographic examination standards for hypertrophic cardiomyopathy]. Zhonghua Yixue Chaosheng Zazhi (Electronic Edition) 2020; 17: 394–408. [Article in Chinese].
[69]
Heart Failure Professional Committee of Chinese Medical Doctor Association, Heart Failure Professional Committee of National Cardiovascular Disease Expert Committee, Editorial Board of Chinese Journal of Heart Failure and Cardiomyopathy. [Chinese expert consensus on diagnosis and treatment of peripartum cardiomyopathy 2021]. Zhonghua Xinli Shuairuo He Xinjibing Zazhi 2021; 5: 3–16. [Article in Chinese].
[70]
Precision Cardiovascular Disease Branch of China International Exchange and Promotion Association for Medical and Healthcare, Chinese Expert Consensus Group on Anticoagulation Therapy for Cardiomyopathy. [Chinese expert consensus on anticoagulation therapy for cardiomyopathy]. Zhongguo Xunhuan Zazhi 2021; 36: 1148–1157. [Article in Chinese].
[71]
Heart Failure Study Group of Cardiovascular Disease Branch of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiovascular Diseases. [Expert consensus on diagnosis and treatment of transthyretin cardiac amyloidosis]. Zhonghua Xinxueguanbing Zazhi 2021; 49: 324–332. [Article in Chinese].
[72]
Chinese Fabry Disease Expert Collaboration Group. [Chinese expert consensus on diagnosis and treatment of Fabry disease (2021 edition)]. Zhonghua Neike Zazhi 2021; 60: 321–330. [Article in Chinese].
Journal of Geriatric Cardiology
Volume 21 Issue 9,
September 2024
Pages 831-845
DOI: 10.26599/1671-5411.2024.09.008
Cite this article:
HU S-S. Valvular heart disease and cardiomyopathy in China: epidemiology and current treatments. Journal of Geriatric Cardiology, 2024, 21(9): 831-845. https://doi.org/10.26599/1671-5411.2024.09.008

198

Views

13

Downloads

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Altmetrics
Published: 28 September 2024
© 2024 JGC All rights reserved
Return